Skip to main content
. 2014 Nov 3;70(2):479–488. doi: 10.1093/jac/dku409

Figure 5.

Figure 5.

Haematoxylin/eosin-stained sections of LabSkin™ exposed to compounds for 24 h. (a) Untreated control. (b) Solvent (0.2% ethanol, v/v). (c) SDS (5%, w/v). (d) Mupirocin at 10× MIC (0.000125%, w/v). (e) Celastrol at 10× MIC (0.001%, w/v). (f) NDGA at 4× MIC (0.0256%, w/v).